Interleukin 6 Drives Durable T Cell-Mediated Immunity to Pancreatic Cancer.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) exhibits poor survival rates, partly due to tumor immune resistance.
• The cytokine interleukin-6 (IL-6) influences T cell polarization and differentiation, potentially impacting anti-tumor responses.

Purpose of the Study:

• To investigate whether elevated IL-6 can stimulate an effective anti-tumor immune response in PDAC.
• To evaluate the therapeutic potential of IL-6 in overcoming immune resistance in PDAC models.

Main Methods:

• Overexpression of IL-6 in KrasG12D/+; Tp53R172H/+; Pdx1-Cre (KPC) cell lines orthotopically implanted in mice (OT-PDACIL6).
• Assessment of survival, tumor growth, histology, and immune cell infiltration (flow cytometry, histology).
• T cell depletion studies and secondary tumor implantation rechallenge.
• Lipid nanoparticle (LNP)-mediated IL-6 mRNA delivery to the pancreas.

Main Results:

• OT-PDACIL6 models demonstrated improved survival, with one cell line (KxPxCx) achieving long-term recurrence-free survival.
• Elevated IL-6 correlated with increased T cells and NK cells, decreased regulatory T cells, and enhanced lymphoid aggregates.
• T cell depletion abrogated the survival advantage, confirming T cell dependency; mice were subsequently immune to tumor rechallenge.
• LNP-based IL-6 delivery lowered tumor burden and promoted anti-tumor T cell phenotypes.

Conclusions:

• Locally high IL-6 concentrations significantly enhance T cell-mediated anti-tumor responses in PDAC.
• IL-6 represents a potent strategy for augmenting anti-PDAC immunity.